Free radicals play an important role in the inflammatory process of
sepsis. We hypothesized that
edaravone, a novel
free radical scavenger, can suppress pathophysiological events and prolong survival in a
neonatal sepsis cecal
ligation and perforation (CLP) model. Of 32 3-day-old anesthetized and mechanically ventilated piglets, 11 received CLP only, 10 received CLP and
edaravone treatment starting 30 min after CLP, and 11 constituted a
sham (control) group. Mean arterial pressure (MAP), heart rate, cardiac output, arterial blood gas, serum total
hydroperoxide,
nitrite and
nitrate,
TNF-alpha, and high-mobility group box 1 (
HMGB1) were measured before CLP and at 1, 3, and 6 h after CLP. Compared with the CLP group, the
edaravone group showed higher MAP at 6 h, lower heart rate at 1 and 3 h, lower total
hydroperoxide at 1 h, lower
nitrite and
nitrate at 3 and 6 h, and higher (although not significantly so) mean cardiac output at 1, 3, and 6 h.
TNF-alpha elevation was delayed from 1 h in the CLP group to 3 h in the
edaravone group. In the
edaravone group,
HMGB1 did not change significantly at any time, whereas in the CLP group, it increased at 6 h. Survival times were longer in the
edaravone group than in the CLP group (15.4 +/- 1.4 vs. 10.2 +/- 1 h; P < 0.005). In addition, each of the serial dilutions of
edaravone had a higher biological
antioxidant potential than
tempol does. In conclusion,
edaravone suppressed
free radicals, delayed the
TNF-alpha surge, and prevented
HMGB1 elevation, thereby maintaining MAP and prolonging survival time in a
neonatal sepsis CLP model.